{"status": "ok", "totalResults": 114, "articles": [{"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (George Budwell)", "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://www.fool.com/investing/2018/09/07/why-exact-sciences-corporation-stock-rocketed-high.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493775%2Frocketman.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences ( NASDAQ:EXAS ), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-\u2026 [+1929 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://www.fool.com/investing/2018/09/06/3-top-big-pharma-stocks-to-buy-now.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493451%2Fpharmaceutical-research.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4543 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/", "title": "A Look At Pfizer's Business And Outlook", "description": "Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, Anti-Infective, Alimentary &amp;Metabolism, Neuroscience, Immunology drugs, along with its Legacy Pharma, Consumer, Biosimilar &amp; Other segment. Legacy Pharma, Consumer, Biosimilar\u2026", "url": "https://www.forbes.com/sites/greatspeculations/2018/09/10/a-look-at-pfizers-business-and-outlook/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fblogs-images.forbes.com%2Fthumbnails%2Fblog_25%2Fpt_25_188249_o.jpg%3Ft%3D1536604325", "publishedAt": "2018-09-10T18:32:00Z", "content": "Share to facebook Share to twitter Share to linkedin The Pfizer company logo is photographed at Pfizer Inc. headquarters, in New York, Monday, Dec. 4, 2017. (AP Photo/Richard Drew) Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, An\u2026 [+9107 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://finance.yahoo.com/news/why-exact-sciences-corporation-stock-100000965.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/cuXO7YplZxOVKts6hNDIHw--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/motleyfool.com/e4f07b38fce926e7eda0457056f7069a", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences (NASDAQ: EXAS), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-m\u2026 [+2147 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "Is Bristol-Myers Squibb Company a Buy?", "description": "This big pharma stock has some baggage, but it also claims two fast-growing blockbusters.", "url": "https://www.fool.com/investing/2018/09/09/is-bristol-myers-squibb-company-a-buy.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493827%2Fpills-foming-question-mark.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-09T10:31:00Z", "content": "Bristol-Myers Squibb ( NYSE:BMY ) stock has underperformed the S&amp;P 500 index so far this year. It's also trailed well behind most of its peers, but it could be worse. Earlier in 2018, Bristol-Myers Squibb (BMS) was down 17%; now the stock has climbed back\u2026 [+3494 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Lilly, Teva, Pfizer & Others Await FDA Decisions in September", "description": "FDA grants approval to 34 new treatments this year so far.", "url": "https://finance.yahoo.com/news/lilly-teva-pfizer-others-await-125812067.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/EyZmh1klWYX.2_4cspNDgQ--~B/aD00MTM7dz02MjA7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/zacks.com/1c294b9de375a124a76eae049179f11e", "publishedAt": "2018-09-07T12:58:12Z", "content": "Like 2017, 2018 is turning out to be a pretty good one for pharma and biotech stocks as far as FDA decisions are concerned. The regulatory body approved 34 novel drugs till August. Last year, the FDA had given nod to 31 new drugs till August and approved 46 d\u2026 [+4154 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status", "description": "Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.", "url": "https://finance.yahoo.com/news/pfizer-apos-skin-disease-drug-145702447.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/RcSGEOiRo4N.qL406x4Pog--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/zacks.com/df5ad064f24e5502d8d1fb68bd8dc90d", "publishedAt": "2018-09-06T14:57:02Z", "content": "Pfizer, Inc. PFE announced that it has received Breakthrough Therapy designation for its pipeline candidate, PF-06651600 from the FDA. The candidate is being developed for alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, \u2026 [+3625 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://finance.yahoo.com/news/3-top-big-pharma-stocks-103000865.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/dMhJrTHQFTunhg6UyrJWsA--~B/aD0zODc7dz01ODA7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/motleyfool.com/cac2a8c273ac939ed15d71ebb32efe02", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4838 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Cory Renauer)", "title": "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?", "description": "Here's what investors need to know about the disappointing results Sangamo announced recently.", "url": "https://www.fool.com/investing/2018/09/06/sangamos-zinc-fingers-fail-again-time-to-walk-away.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493528%2Fbusinessman-in-shock-hands-on-head-laptop-surprise-investment-getty.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T12:48:00Z", "content": "An attempt to edit genetic flaws on the fly didn't work nearly as well as hoped for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ), and the stock just took a dip. Is it time to cut and run? Before investors do any panic trading, there are a few things they need t\u2026 [+4435 chars]"}, {"source": {"id": null, "name": "Fiercebiotech.com"}, "author": "Nick Paul", "title": "After midphase flop, Pfizer taps Cytoo for help identifying DMD targets", "description": "Pfizer has teamed up with Cytoo to work on a Duchenne muscular dystrophy (DMD) target discovery platform. The early-stage alliance comes a week after Pfizer halted development of domagrozumab in DMD because of lackluster midphase data.", "url": "https://www.fiercebiotech.com/biotech/after-midphase-flop-pfizer-taps-cytoo-for-help-identifying-dmd-targets?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercebiotech/1536316463/PfizerHQsignone.jpg/PfizerHQsignone.jpg?vOOHCcNj1UrRzDdMkYiDtHlm6yj70xsd", "publishedAt": "2018-09-07T10:35:16Z", "content": "Pfizer has teamed up with Cytoo to work on a Duchenne muscular dystrophy (DMD) target discovery platform. The early-stage alliance (PDF) comes a week after Pfizer halted development of domagrozumab in DMD because of lackluster midphase data. Domagrozumab\u2019s in\u2026 [+1963 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "Why Sangamo Therapeutics, Inc. Sank Again Today", "description": "Disappointing interim results for its gene-editing therapy continued to weigh on the biotech stock.", "url": "https://www.fool.com/investing/2018/09/06/why-sangamo-therapeutics-inc-sank-again-today.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493757%2Fdoctor-with-dna-and-question-mark.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T21:00:00Z", "content": "What happened Shares of Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) were down 10.5% as of 3:34 p.m. EDT on Thursday. This marked the second consecutive day of double-digit percentage declines following the biotech's interim update from a phase 1/2 clinical stu\u2026 [+2158 chars]"}, {"source": {"id": null, "name": "Rsc.org"}, "author": "Paul Dingwall, Andreas Greb, Lor\u00e8ne N. S. Crespin, Ricardo Labes, Biagia Musio, Jian-Siang Poh, Patrick Pasau, David C. Blakemore, Steven V. Ley", "title": "C\u2013H functionalisation of aldehydes using light generated, non-stabilised diazo compounds in flow", "description": "Chem. Commun., 2018, Advance Article DOI : 10.1039/C8CC06202A, Communication Open Access &nbsp This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. Paul Dingwall, Andreas Greb, Lor\u00e8ne N. S. Crespin, Ricardo Labes, Biagia Musio, \u2026", "url": "https://pubs.rsc.org/en/content/articlelanding/2018/cc/c8cc06202a", "urlToImage": null, "publishedAt": "2018-09-10T23:00:00Z", "content": "* Corresponding authors a Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK E-mail: svl1000@cam.ac.uk Web: http://www.leygroup.ch.cam.ac.uk b UCB Biopharma SPRL, Chemical Research R5, Chemin du Foriest 1420, Braine-L\u2019Alle\u2026 [+74 chars]"}, {"source": {"id": null, "name": "Fiercebiotech.com"}, "author": "Phil Taylor", "title": "Allogene raises another $120M for off-the-shelf CAR-T programs", "description": "Allogene\u2019s bustling first few months has continued with a $120 million private financing round that will help it advance its off-the-shelf CAR-T therapies for cancer.", "url": "https://www.fiercebiotech.com/biotech/allogene-raises-120m-more-for-off-shelf-car-t-programs?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercebiotech/1536237546/gold_piggy_bank.jpg/gold_piggy_bank.jpg?fAca5m0txEEIn7c85yHItb9bxKQSJq2F", "publishedAt": "2018-09-06T12:40:15Z", "content": "Allogene\u2019s bustling first few months has continued with a $120 million private financing round that will help it advance its off-the-shelf CAR-T therapies for cancer. The biotech\u2014formed by Kite Pharma executives Arie Belldegrun and David Chang\u2014came out of ste\u2026 [+2415 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Arlene Weintraub, Contributor, Arlene Weintraub, Contributor https://www.forbes.com/sites/arleneweintraub/", "title": "Will Trump's Pharma Shaming Bring Down Drug Prices? Not Likely, Poll Says", "description": "President Trump promised \u201cvoluntary massive drops in prices\u201d from Big Pharma. Americans are skeptical.", "url": "https://www.forbes.com/sites/arleneweintraub/2018/09/06/will-trumps-pharma-shaming-bring-down-drug-prices-not-likely-poll-says/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fspecials-images.forbesimg.com%2Fdam%2Fimageserve%2F813697758%2F960x0.jpg%3Ffit%3Dscale", "publishedAt": "2018-09-06T13:24:00Z", "content": "Share to facebook Share to twitter Share to linkedin High drug costs are a concern for voters in the 2018 midterm elections, a new poll reveals. (Source: Getty Royalty Free) In July, Pfizer put plans to raise the prices of some of its products on hold after P\u2026 [+6873 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/", "title": "A Snapshot of Bristol-Myers Squibb's Business & Outlook", "description": "Bristol-Myers Squibb (NYSE:BMY) generates its revenues from its Oncology, Cardiovascular, Immunology, Virology, along with its Mature Drugs &amp; Other segment. Oncology accounts for over 40% of the company\u2019s total revenues, and will likely see steady growth \u2026", "url": "https://www.forbes.com/sites/greatspeculations/2018/09/10/a-snapshot-of-bristol-myers-squibbs-business-outlook/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fblogs-images.forbes.com%2Fthumbnails%2Fblog_25%2Fpt_25_188242_o.jpg%3Ft%3D1536603123", "publishedAt": "2018-09-10T18:12:00Z", "content": "Share to facebook Share to twitter Share to linkedin Bristol-Myers Squibb Co. brand medication sits on a pharmacy shelf in Provo, Utah. (Photographer: George Frey/Bloomberg) Bristol-Myers Squibb (NYSE:BMY) generates its revenues from its Oncology, Cardiovascu\u2026 [+7213 chars]"}, {"source": {"id": null, "name": "Acs.org"}, "author": "nobody@acs.org(\"\")", "title": "For District I director: Katherine L. Lee", "description": "", "url": "https://cen.acs.org/acs-news/elections/District-director-Katherine-L-Lee/96/i36?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+cen_latestnews+%28Chemical+%26+Engineering+News%3A+Latest+News%29", "urlToImage": "https://cen.acs.org/content/dam/cen/96/36/09636-acsnews4-lee.jpg", "publishedAt": "2018-09-07T13:15:22Z", "content": "Northeastern Section. Pfizer, Cambridge, Mass. Academic record: Yale University, B.S., summa cum laude, with distinction in chemistry, 1991; Massachusetts Institute of Technology, Ph.D., organic chemistry, 1996; University of Texas, Austin, postdoctoral fello\u2026 [+6268 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Joshua Cohen, Contributor, Joshua Cohen, Contributor https://www.forbes.com/sites/joshuacohen/", "title": "Tanezumab's Phase 3 Results: A Promising Sign For Non-Opioid Pain Treatments", "description": "As the opioid crisis has unfolded concerns have grown about dependency and the potentially addictive nature of opioid-based pain treatments. Having satisfactory non-opioid treatment alternatives will need to be an integral part of effective pain management.", "url": "https://www.forbes.com/sites/joshuacohen/2018/09/06/tanezumabs-phase-3-results-a-promising-sign-for-non-opioid-pain-treatments/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fspecials-images.forbesimg.com%2Fdam%2Fimageserve%2F8850fc86753847019b09c48891d47021%2F960x0.jpg%3Ffit%3Dscale", "publishedAt": "2018-09-06T12:11:00Z", "content": "Share to facebook Share to twitter Share to linkedin This Wednesday, March 29, 2017 photo shows a syringe involved in an experimental non-opioid pain medication trial at the Altoona Center for Clinical Research in Altoona, Pa. With about 2 million Americans a\u2026 [+11353 chars]"}, {"source": {"id": null, "name": "Seekingalpha.com"}, "author": "Augury Investments", "title": "Exact Sciences: Can It Make Colonoscopies A Thing Of The Past?", "description": "Colorectal cancer and the market for screening for this cancer is huge. I believe that Non-colonoscopy methods available to screening will become the norm as th", "url": "https://seekingalpha.com/article/4205366-exact-sciences-can-make-colonoscopies-thing-past", "urlToImage": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "publishedAt": "2018-09-10T18:44:23Z", "content": "Introduction Colorectal cancer is the 4th highest cancer killer in America killing around 268,000 people each year. One of the reasons that colorectal cancer is such a terrible killer is the fact that people don't get screened enough to catch the disease earl\u2026 [+7644 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Tom Aspray, Contributor, Tom Aspray, Contributor https://www.forbes.com/sites/tomaspray/", "title": "Are Overbought Dow Stocks Stalling The Market's Rally?", "description": "After a record breaking performance in August, stocks retreated at the start of September. Was this just a normal technical correction and what role did the high profile, overbought Dow stocks play in the pullback? What levels should you be watching in the we\u2026", "url": "https://www.forbes.com/sites/tomaspray/2018/09/09/are-overbought-dow-stocks-stalling-the-markets-rally/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fspecials-images.forbesimg.com%2Fdam%2Fimageserve%2F42830528%2F960x0.jpg%3Ffit%3Dscale", "publishedAt": "2018-09-09T11:41:00Z", "content": "After a record-breaking performance by many of the market averages in August, things were not so easy after the Labor Day holiday. As expected, volume increased significantly, as traders had few excuses left to stay on vacation. Traders work on the floor of t\u2026 [+14671 chars]"}, {"source": {"id": null, "name": "Rbtereport.com"}, "author": null, "title": "Estrogen Therapeutics Market In Depth Analysis Of Historical, Present and Futuristic Industry Data 2018-2022 - RBTE Report", "description": "RBTE Report Estrogen Therapeutics Market In Depth Analysis Of Historical, Present and Futuristic Industry Data 2018-2022 RBTE Report Estrogen Therapeutics Market 2018-2022 details out critical market data like Market size, current revenue & expected revenue i\u2026", "url": "https://www.rbtereport.com/2018/09/09/estrogen-therapeutics-market-in-depth-analysis-of-historical-present-and-futuristic-industry-data-2018-2022/", "urlToImage": "https://media.defense.gov/2017/Oct/13/2001826755/780/780/0/171011-F-RA202-001.JPG", "publishedAt": "2018-09-09T19:34:00Z", "content": "Estrogen Therapeutics Market 2018-2022 details out critical market data like Market size, current revenue &amp; expected revenue in the coming years. The report discusses top players in the North America, Europe, Asia pacific, South America and Other regions \u2026 [+2932 chars]"}]}